GlucaGon, a recombinant DNA product, was developed as a nasal formulation of glucagon for the treatment of insulin-induced hypoglycemia. Glucagon is widely used by insulin dependent diabetic patients as an emergency treatment for severe hypoglycemic reactions. Use of genetically engineered glucagon by both intranasal and intramuscular methods has a similar effect on hepatic glucose production rate as natural glucagon from pancreatic extraction.